BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36870907)

  • 1. COVID 19 convalescent plasma: Is there still a place for CCP?
    Moog R
    Transfus Apher Sci; 2023 Apr; 62(2):103680. PubMed ID: 36870907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes.
    Yokoyama APH; Wendel S; Bonet-Bub C; Fachini RM; Dametto APF; Blumm F; Dutra VF; Candelaria GTP; Sakashita AM; Machado RRG; Fontão-Wendel R; Hamerschlak N; Achkar R; Assunção MSC; Scuracchio P; Nudelman V; Pastore L; Pinho JRR; Ben MD; Filho RK; Marra AR; Amano MT; Kallás EG; Helito AS; de Carvalho CRR; Araujo DB; Durigon EL; Camargo AA; Rizzo LV; Reis LFL; Kutner JM
    Transfusion; 2021 Aug; 61(8):2295-2306. PubMed ID: 34173248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.
    Wirz OF; Röltgen K; Stevens BA; Pandey S; Sahoo MK; Tolentino L; Verghese M; Nguyen K; Hunter M; Snow TT; Singh AR; Blish CA; Cochran JR; Zehnder JL; Nadeau KC; Pinsky BA; Pham TD; Boyd SD
    Front Immunol; 2021; 12():739037. PubMed ID: 34594341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study.
    Bartelt LA; Markmann AJ; Nelson B; Keys J; Root H; Henderson HI; Kuruc J; Baker C; Bhowmik DR; Hou YJ; Premkumar L; Cornaby C; Schmitz JL; Weiss S; Park Y; Baric R; de Silva AM; Lachiewicz A; Napravnik S; van Duin D; Margolis DM
    mBio; 2022 Oct; 13(5):e0175122. PubMed ID: 36135380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19.
    Sanz C; Nomdedeu M; Pereira A; Sauleda S; Alonso R; Bes M; Brillembourg H; García-Vidal C; Millan A; Martínez-Llonch N; Pirón M; Puerta-Alcalde P; Puig L; Rico V; Soriano A
    Transfusion; 2022 May; 62(5):974-981. PubMed ID: 35338710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients.
    Franchini M; Focosi D; Percivalle E; Beccaria M; Garuti M; Arar O; Pecoriello A; Spreafico F; Greco G; Bertacco S; Ghirardini M; Santini T; Schiavulli M; Stefania M; Gagliardo T; Sammartino JC; Ferrari A; Zani M; Ballotari A; Glingani C; Baldanti F
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.
    Li L; Yang R; Wang J; Lv Q; Ren M; Zhao L; Chen H; Xu H; Xie S; Xie J; Lin H; Li W; Fang P; Gong L; Wang L; Wu Y; Liu Z
    Transfusion; 2020 Aug; 60(8):1773-1777. PubMed ID: 32491199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname.
    Bihariesingh-Sanchit R; Bansie R; Ramdhani N; Mangroo R; Bustamente D; Diaz E; Fung A Foek C; Thakoer I; Vreden S; Choudhry Z; van 't Wout AB; Diavatopoulos DA; Nierich AP
    mBio; 2023 Apr; 14(2):e0337922. PubMed ID: 36815780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds.
    Larkey NE; Ewaisha R; Lasho MA; Roforth MM; Granger D; Jerde CR; Wu L; Gorsh A; Klassen SA; Senefeld JW; Joyner MJ; Baumann NA; Theel ES; Mills JR
    Microbiol Spectr; 2022 Aug; 10(4):e0115422. PubMed ID: 35862939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
    De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
    Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convalescent plasma in hospitalized pediatric and obstetric coronavirus disease 2019 (COVID-19) patients.
    Ikeda S; Benzi E; Hensch LA; Devaraj S; Hui SR; Gandhi M; Fox KA; Teruya J; Munoz FM
    Pediatr Int; 2022 Jan; 64(1):e15407. PubMed ID: 36326636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies.
    Jazbec K; Jež M; Žiberna K; Mali P; Ramšak Ž; Potokar UR; Kvrzić Z; Černilec M; Gracar M; Šprohar M; Jovanovič P; Vuletić S; Rožman P
    Virol J; 2023 Mar; 20(1):53. PubMed ID: 36973781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programme-The South African Experience.
    Glatt TN; Hilton C; Nyoni C; Swarts A; Swanevelder R; Cowley J; Mmenu C; Moyo-Gwete T; Moore PL; Kutama M; Jaza J; Phayane I; Brits T; Koekemoer J; Jentsch U; Nelson D; van den Berg K; Vermeulen M
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case-control study.
    Klein MN; Wang EW; Zimand P; Beauchamp H; Donis C; Ward MD; Martinez-Hernandez A; Tabatabai A; Baddley JW; Bloch EM; Mullins KE; Fontaine MJ
    J Clin Pathol; 2022 Aug; 75(8):564-571. PubMed ID: 33893156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody profiles in COVID-19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment.
    Bagri A; de Assis RR; Tsai CT; Simmons G; Mei ZW; Von Goetz M; Gatmaitan M; Stone M; Di Germanio C; Martinelli R; Darst O; Rioveros J; Robinson PV; Ward D; Ziman A; Seftel D; Khan S; Busch MP; Felgner PL; Corash LM
    Transfusion; 2022 Mar; 62(3):570-583. PubMed ID: 35128658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge.
    Tayyar R; Wong LK; Dahlen A; Shu E; Pandey S; Liu AY
    Transpl Infect Dis; 2023 Apr; 25(2):e14055. PubMed ID: 36929619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study.
    Alsharidah S; Ayed M; Ameen RM; Alhuraish F; Rouheldeen NA; Alshammari FR; Embaireeg A; Almelahi M; Adel M; Dawoud ME; Aljasmi MA; Alshammari N; Alsaeedi A; Al-Adsani W; Arian H; Awad H; Alenezi HA; Alzafiri A; Gouda EF; Almehanna M; Alqahtani S; Alshammari A; Askar MZ
    Int J Infect Dis; 2021 Feb; 103():439-446. PubMed ID: 33285283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation.
    Van Rompay KKA; Olstad KJ; Sammak RL; Dutra J; Watanabe JK; Usachenko JL; Immareddy R; Roh JW; Verma A; Shaan Lakshmanappa Y; Schmidt BA; Di Germanio C; Rizvi N; Liu H; Ma ZM; Stone M; Simmons G; Dumont LJ; Allen AM; Lockwood S; Pollard RE; Ramiro de Assis R; Yee JL; Nham PB; Ardeshir A; Deere JD; Jain A; Felgner PL; Coffey LL; Iyer SS; Hartigan-O'Connor DJ; Busch MP; Reader JR
    PLoS Pathog; 2022 Apr; 18(4):e1009925. PubMed ID: 35443018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial.
    Bégin P; Callum J; Heddle NM; Cook R; Zeller MP; Tinmouth A; Fergusson DA; Cushing MM; Glesby MJ; Chassé M; Devine DV; Robitalle N; Bazin R; Shehata N; Finzi A; McGeer A; Scales DC; Schwartz L; Turgeon AF; Zarychanski R; Daneman N; Carl R; Amorim L; Gabe C; Ellis M; Sachais BS; Loftsgard KC; Jamula E; Carruthers J; Duncan J; Lucier K; Li N; Liu Y; Armali C; Kron A; Modi D; Auclair MC; Cerro S; Avram M; Arnold DM
    Trials; 2021 May; 22(1):323. PubMed ID: 33947446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.